Impact of Peri-operative tEstosterone Levels on oNcological and Functional Outcomes in RadiCal prostatEctomy

Inclusion criteria 1. Men aged 18 years or older 2. Histologically confirmed prostate cancer 3. Radical prostatectomy performed as primary treatment 4. At least one-sided nerve-sparing procedure performed 5. Non-metastatic disease (cN0M0) based on the use of nomograms or imaging 6. Undetectable PSA level (\<0.1 µg/l or unmeasurable according to local protocol) within six weeks following RP 7. A preoperative minimal sexual function, defined as a score of 40 points or more (out of 100) for the EPIC-26 sexual function domain 8. Testosterone deficiency, defined as total testosterone \<8 nmol/L, or total testosterone between 8-12 nmol/L with free testosterone \<225 pmol/L, measured on two separate occasions, with normal or elevated luteinising hormone (LH) Exclusion criteria 1. Prior prostate cancer treatment, including but not limited to anti-hormonal therapy, radiotherapy, or brachytherapy (active surveillance allowed) 2. Previous use of testosterone therapy for any reason 3. Pathological stage pT3b or pT4 in the RP specimen 4. Positive surgical margin(s) with ISUP grade 4 or 5 in the RP specimen 5. Presence of metastatic lymph nodes if pelvic lymph node dissection was performed 6. History of male breast cancer or liver tumour 7. Uncontrolled hypertension 8. General contraindications for TRT 9. Allergy for components in TRT agent or placebo 10. Use of vitamin K antagonists 11. Body mass index (BMI) \>30 kg/m²